The Food and Drug Administration sought to defend itself from critics who say it has played a part in the soaring cost of the EpiPen allergy treatment.

The head of drug regulation said Wednesday that the FDA has a part to play to ensure generic competition and drive down costs. Republican lawmakers have criticized the agency because the EpiPen has no generic competition, letting the manufacturer, Mylan Pharmaceuticals, raise the price to $600.